Shanghai Zhenge Biotech Raises Usd 100 Million Round C Led By Goldman Sachs Asset Management And Sofina

Jan 11, 2022•over 3 years ago

Amount Raised

$100 Million

Shanghai

Description

Shanghai ZhenGe Biotech Co., Ltd. ("ZhenGe Biotech" or "the Company") announced the completion of round C financing of US $100 million, led by Goldman Sachs Asset Management and Sofina. Also investing were Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital and Cowin Capital.

Company Information

Company

Zhen Ge Biotech

Location

Shanghai, Shanghai, China

About

Shanghai ZhenGe Biotech was founded in 2017. ZhenGe Biotech's core business is macromolecular biological drug CDMO service, mammalian cell culture medium development and production, etc. Specifically, its services include: macromolecule developability analysis, cell line development, process development and optimization, pilot production, clinical sample production and commercial CMO services, process characterization and validation research, drug analysis services, cell culture medium formulation development and commercial production, etc. SOURCE Shanghai ZhenGe Biotech

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Shanghai Zhenge Biotech Raises Usd 100 Million Round C Led By Goldman Sachs Asset Management And Sofina

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information